Replies to post #35249 on Biotech Values

[Biowatch]

>>Lucentis – 80% of the $153M in sales were from patients who switched treatment from Macugen, Visudyne, or Avastin. (Source: DNA CC)<<

It would be interesting to see the breakdown of how many switched from which drug.

Visudyne sales presumably hurt the most with all the alternatives out there, but their sales have dropped already.